Abstract
Current Danish guidelines in HER2-positive metastatic breast cancer (mBC) recommend the combination of trastuzumab with one of several chemotherapeutic agents for 3rd line or later treatments. This study aims to describe treatment of HER2-positive mBC in 3rd line or later after previous treatment with T-DM1 for mBC in a Danish real-world setting.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
